Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04081389
Title Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Roswell Park Cancer Institute
Indications

triple-receptor negative breast cancer

Therapies

Celecoxib + Cyclophosphamide + Doxorubicin + Interferon alpha-2b + Paclitaxel + Rintatolimod

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Roswell Park Cancer Institute Recruiting Buffalo New York 14263 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field